Market Place
Sourcing Support
Olema Oncology Presents Updated Palazestrant Data at SABCS
10 Dec 2024 //
GLOBENEWSWIRE
Olema Oncology Announces FDA Clearance for OP-3136, KAT6 Inhibitor
09 Dec 2024 //
GLOBENEWSWIRE
Olema Oncology Report Inducement Grants Under Nasdaq LR 5635(c)(4)
03 Dec 2024 //
GLOBENEWSWIRE
Olema to Present Data on Palazestrant + Ribociclib at Symposium
25 Nov 2024 //
GLOBENEWSWIRE
Olema Oncology Reports Q3 2024 Financial Results & Corporate Update
12 Nov 2024 //
GLOBENEWSWIRE
Olema Oncology to Participate in Upcoming Investor Conferences
06 Nov 2024 //
GLOBENEWSWIRE
Olema Oncology Reports Inducement Grants Under Nasdaq LR5635(c)(4)
04 Nov 2024 //
GLOBENEWSWIRE
Olema Oncology Shows Anti-Tumor Data for OP-3136 at ENA
23 Oct 2024 //
GLOBENEWSWIRE
Olema To Present Preclinical Data At EORTC-NCI-AACR
09 Oct 2024 //
GLOBENEWSWIRE
Olema Reports Grants Under Nasdaq Rule 5635(c)(4)
03 Oct 2024 //
GLOBENEWSWIRE
Olema Oncology Reports Inducement Grants Under Nasdaq LR 5635(c)(4)
02 Oct 2024 //
GLOBENEWSWIRE
Olema Oncology Reports Inducement Grants Under Nasdaq Listing
04 Sep 2024 //
GLOBENEWSWIRE
Olema Oncology To Attend Morgan Stanley Healthcare Conference
21 Aug 2024 //
GLOBENEWSWIRE
Olema Oncology Reports Q2 2024 Results And Corporate Update
06 Aug 2024 //
GLOBENEWSWIRE
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
02 Aug 2024 //
GLOBENEWSWIRE
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
02 Jul 2024 //
GLOBENEWSWIRE
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04 Jun 2024 //
GLOBENEWSWIRE
Olema Oncology to Participate in Upcoming Investor Conferences in June
28 May 2024 //
GLOBENEWSWIRE
Olema Presents Promising Palazestrant + Ribociclib Data At ESMO Breast Congress
15 May 2024 //
GLOBENEWSWIRE
Olema Palazestrant+Ribociclib Breast Cancer Data At ESMO
08 May 2024 //
GLOBENEWSWIRE
Olema Oncology Q1 2024 Financials, Corporate Update
08 May 2024 //
GLOBENEWSWIRE
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
02 May 2024 //
GLOBENEWSWIRE
Olema Oncology to Participate in Upcoming Investor Conferences in May
01 May 2024 //
GLOBENEWSWIRE
Olema to Participate in Canaccord Genuity 2024 Horizons in OVC
08 Apr 2024 //
GLOBENEWSWIRE
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
02 Apr 2024 //
GLOBENEWSWIRE
Olema Oncology Reports Fourth Quarter and Full-Year 2023 Financial Results
11 Mar 2024 //
GLOBENEWSWIRE
Olema Oncology Announces Publication of Data Highlighting Palazestrant™s Ability
06 Mar 2024 //
GLOBENEWSWIRE
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04 Mar 2024 //
GLOBENEWSWIRE
Olema Oncology to Participate in Upcoming Investor Conferences
06 Feb 2024 //
GLOBENEWSWIRE
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
02 Feb 2024 //
GLOBENEWSWIRE
Olema Oncology Nominates OP-3136, an Orally Bioavailable KAT6 Inhibitor
08 Jan 2024 //
GLOBENEWSWIRE
Olema Oncology to Present at 42nd Annual J.P. Morgan Healthcare Conference
02 Jan 2024 //
GLOBENEWSWIRE
Olema Announces Palazestrant Demonstrates Combinability with CDK4/6 Inhibitors
05 Dec 2023 //
GLOBENEWSWIRE
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04 Dec 2023 //
GLOBENEWSWIRE
Olema to Present Palazestrant Data in Combination with CDK4/6 Inhibitors
28 Nov 2023 //
GLOBENEWSWIRE
Olema Oncology Reports Third Quarter 2023 Financial Results
07 Nov 2023 //
GLOBENEWSWIRE
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
02 Nov 2023 //
GLOBENEWSWIRE
Olema Oncology to Participate in Upcoming Investor Conferences in November
01 Nov 2023 //
GLOBENEWSWIRE
Olema Oncology Announces Positive Phase 2 Study Results for Palazestrant
22 Oct 2023 //
GLOBENEWSWIRE
Olema Appoints Oncology Biotech Executive Scott Garland to Board of Directors
17 Oct 2023 //
GLOBENEWSWIRE
Olema Announces Phase 2 Monotherapy Clinical Results to be Presented
16 Oct 2023 //
GLOBENEWSWIRE
Olema Oncology KAT6 Inhibitor Compounds Demonstrate Potent Anti-Tumor Activity
12 Oct 2023 //
GLOBENEWSWIRE
Olema Oncology Announces Expansion of Collaboration Agreement with Novartis
10 Oct 2023 //
GLOBENEWSWIRE
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
03 Oct 2023 //
GLOBENEWSWIRE
Olema Oncology Announces New Preclinical KAT6 Inhibitor Data to be Presented
20 Sep 2023 //
GLOBENEWSWIRE
Olema Oncology to Participate in Upcoming Investor Conferences
06 Sep 2023 //
GLOBENEWSWIRE
Olema Oncology Announces Combined Financing for Up to $180 Million
05 Sep 2023 //
GLOBENEWSWIRE
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
05 Sep 2023 //
GLOBENEWSWIRE
Olema Oncology Reports Second Quarter 2023 Financial Results
08 Aug 2023 //
GLOBENEWSWIRE
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
02 Aug 2023 //
GLOBENEWSWIRE
Olema Oncology to Present at the Canaccord Genuity 43rd Annual Growth Conference
01 Aug 2023 //
GLOBENEWSWIRE
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
05 Jul 2023 //
GLOBENEWSWIRE
Olema Oncology traces pivotal trial pathway after business challenges
22 Jun 2023 //
PHARMACEUTICAL TECHNOLOGY
We`re Keeping An Eye On Olema Pharmaceuticals` (NASDAQ:OLMA) Cash Burn Rate
11 Jun 2023 //
SIMPLYWALL
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
02 Jun 2023 //
GLOBENEWSWIRE
Olema Oncology to Present at the 2023 Jefferies Healthcare Conference
30 May 2023 //
GLOBENEWSWIRE
Olema gives update to breast cancer drug at center of layoffs, 2021 data leak
11 May 2023 //
ENDPTS
Olema Oncology Reports1Q 2023 FYR and Provides Corporate Update
09 May 2023 //
GLOBENEWSWIRE
Olema Oncology Announces Upcoming Poster Presentation at the 2023 ESMO
08 May 2023 //
GLOBENEWSWIRE
